Tongjitang's 1st-qtr 2008 revenue falls 29%

22 June 2008

Tongjitang Chinese Medicines' first-quarter 2008 net revenues decreased 29% year-on-year to 105.8 million renminbi ($15.1 million), as sales of Xianling Gubao fell 39% to 70.3 million renminbi and other core products declined 29% to 13.5 million remnimbi.

During the period, the Chinese drugmaker says net income totaled 11.9 million, or 0.35 renminbi per American Depositary Share, 0.09 remnimbi per standard share. According to the firm, this per share performance reflects the 29% increase in the weighted average number of shares used in the calculations, resulting from the company's initial public offering in March 2007.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight